Pilot clinical study of Taxifolin Aqua effect in patients with amnestic mild cognitive impairment
Taxifolin (dihydroquercetin), a potent antioxidant flavonoid, shows promise for neurodegenerative conditions. Our pilot study aimed at evaluation the efficacy and safety of Taxifolin in patients with amnestic mild cognitive impairment (aMCI) and monitored a set of blood measures. Twenty-three patients (18 female; aged 53-87) received dihydroquercetin oral solution for 8 weeks with a 4-week…
Read original article on Frontiers in Psychiatry | New and Recent Articles →Related news
-
Beauty, Being, and Becoming
United States
-
30 Beautiful Things Happening Right Now
United States
-
Loss plus adversity: posttraumatic stress and prolonged grief three years after the 2023 Türkiye earthquakes
Switzerland
-
Efficacy and neural mechanisms of transcutaneous auricular vagus nerve stimulation for chronic insomnia: a study protocol for a randomized controlled trial
Switzerland
-
The real experience and coping styles of emergence delirium in patients after radical lung cancer surgery: a qualitative study
Switzerland
-
Adolescent non-suicidal self-injury scale – short form: revision and evaluation of its reliability and validity
Switzerland
-
Family socioeconomic status and attention-deficit/hyperactivity disorder symptoms in preschool children: a cross-sectional study of 21,366 parent–child dyads in Yan’an, western China
Switzerland
-
Effect of age-friendly community degree on the cognitive function of older adults
Switzerland